Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Insmed Incorporated - Common Stock
(NQ:
INSM
)
206.78
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Insmed Incorporated - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Which stocks are gapping on Tuesday?
↗
June 10, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Via
Chartmill
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday
↗
June 10, 2025
Via
Benzinga
Insmed Stock Soars Pre-market After Lung Disease Drug Achieves Positive Results In Mid-Stage Trial: Retail Gets More Bullish
↗
June 10, 2025
Insmed said that it will immediately engage with the U.S. Food and Drug Administration (FDA) regarding a late-stage study design following the positive results from the mid-stage trial.
Via
Stocktwits
Topics
Death
How Do Investors Really Feel About Insmed?
↗
May 23, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
Is Insmed Gaining or Losing Market Support?
↗
May 01, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years
↗
March 05, 2025
Via
Benzinga
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia
↗
June 10, 2025
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment.
Via
Investor's Business Daily
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
May 13, 2025
Via
Benzinga
Analyst Expectations For Insmed's Future
↗
May 12, 2025
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
↗
May 09, 2025
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
May 05, 2025
Via
Benzinga
Earnings Scheduled For February 20, 2025
↗
February 20, 2025
Via
Benzinga
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
↗
February 14, 2025
Via
Benzinga
Peering Into Insmed's Recent Short Interest
↗
February 14, 2025
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
↗
April 25, 2025
Via
Benzinga
In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio?
↗
April 20, 2025
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences.
Via
Benzinga
Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years
↗
April 15, 2025
Via
Benzinga
Friday's after hours session: top gainers and losers
↗
April 11, 2025
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
Insmed Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
↗
February 11, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years
↗
February 05, 2025
Via
Benzinga
A technical analysis of INSMED INC (NASDAQ:INSM).
↗
March 28, 2025
INSMED INC (NASDAQ:INSM) Reveals Intriguing Technical Aspects. Indications Suggest NASDAQ:INSM Could Be on the Verge of a Breakout. Here's What You Need to Know.
Via
Chartmill
$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
↗
March 25, 2025
Via
Benzinga
Expert Outlook: Insmed Through The Eyes Of 13 Analysts
↗
March 19, 2025
Via
Benzinga
One Vanguard Index Fund to Buy That May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst
↗
March 15, 2025
Via
The Motley Fool
Topics
Stocks
Are Small-Cap Stocks A Buy After Russell 2000 Correction?
↗
March 06, 2025
Investors are questioning the value of small-cap stocks, as reflected by Russell 2000's 15% drop. Some top stocks saw even bigger declines.
Via
Benzinga
First Trust's New Small-Cap ETF Aims To Combine Growth With Income
↗
February 28, 2025
First Trust launches actively managed FTKI ETF, using buy-write strategy for steady income and small-cap exposure. Expense ratio is 0.85%.
Via
Benzinga
Topics
ETFs
Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says
↗
February 25, 2025
RBC Capital initiates Insmed with an Outperform rating, citing brensocatib's launch potential and Arikayce's growth. FDA decision on brensocatib due August 2025.
Via
Benzinga
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
February 25, 2025
Via
Benzinga
Goldman Sachs Sees High Merger Odds For This Large-Cap Biopharma In Trump 2.0 Era: Retail Has Been Alert
↗
January 16, 2025
Insmed specializes in treatments for rare and serious diseases and is currently advancing its lead asset, brensocatib, a potential first-in-class therapy for bronchiectasis.
Via
Stocktwits
Topics
Government
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today